Singapore, Aug. 31 -- Fosun Pharma continued to strengthen its innovation-led growth strategy in the first half of 2026, supported by increasing contributions from innovative drugs, pipeline progress and global expansion across its pharmaceutical portfolio.

The company recorded operating revenue of RMB20.377 billion during the period.

Revenue from innovative drugs increased 13.84% year-on-year, with their contribution to Fosun Pharma's pharmaceutical business rising to 33.35%.

The group said innovative medicines are becoming an increasingly important growth engine as commercialisation accelerates across both domestic and international markets.

Fosun Pharma's innovative biopharmaceutical subsidiary Henlius recorded revenue of RMB3.5882...